Literature DB >> 22099092

Seasonal influenza A virus in feces of hospitalized adults.

Martin C W Chan1, Nelson Lee, Paul K S Chan, K F To, Rity Y K Wong, Wing-Shan Ho, Karry L K Ngai, Joseph J Y Sung.   

Abstract

In a cohort of hospitalized adults with seasonal influenza A in Hong Kong, viral RNA was frequently (47%) detected in stool specimens. Viable virus was rarely isolated. Viral RNA positivity had little correlation with gastrointestinal symptoms and outcomes. In vitro studies suggested low potential for seasonal influenza viruses to cause direct intestinal infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22099092      PMCID: PMC3310558          DOI: 10.3201/eid1711.110205

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Although influenza predominantly causes respiratory diseases, gastrointestinal signs such as diarrhea and vomiting are not uncommonly reported, particularly among young, hospitalized children (8%–38%) and immunocompromised persons (–). Influenza virus RNA has been detected in feces, but its role is unknown (–). We investigated fecal viral RNA shedding in a large cohort of hospitalized adults with seasonal influenza A in Hong Kong Special Administrative Region, People’s Republic of China. The potential of seasonal influenza viruses to cause direct intestinal infections was examined.

The Study

We conducted a prospective, observational study among adults hospitalized with laboratory-confirmed seasonal influenza A infections during 2006–2009. Hospital admission, diagnosis, and management procedures have been described (). Briefly, patients were admitted if severe symptoms, respiratory or cardiovascular complications, or exacerbations of underlying conditions developed. When the patients sought care, nasopharyngeal aspirates (NPAs) were collected for diagnosis by using immunofluorescence assay or reverse transcription PCR. Patients with confirmed influenza A were recruited if they were >18 years of age and sought care within 1 week of illness onset. Patients with pandemic (H1N1) 2009 virus infections were excluded and reported separately (). After providing written, informed consent, patients were asked to submit 1 stool specimen for viral RNA detection during hospitalization, regardless of gastrointestinal symptoms. Clinical information was prospectively recorded (). For comparison, fecal shedding of respiratory syncytial virus (RSV) and parainfluenza virus (PIV) were studied during a 10-month period by using a similar approach. Ethical approval for the study was obtained from the institutional review boards of The Chinese University of Hong Kong. All stool specimens were subjected to influenza viral RNA detection by using quantitative real-time reverse transcription PCR targeting the matrix gene (). If positive, virus subtyping was performed by using H1- and H3-specific conventional PCRs. Freshly collected stool specimens during 1 seasonal peak were simultaneously subjected to viral RNA detection and virus isolation by using MDCK cells. Detailed methods for fecal detection of influenza viruses and RSV and PIV are provided in the Technical Appendix. Lectin histochemical analysis and double immunofluorescence staining were used to study the distribution of influenza virus receptors on human small and large intestinal tissues. An in vitro virus binding study on intestinal tissues was also performed by using inactivated human virus isolates of subtypes H1N1 (A/HongKong/CUHK-13003/2002) and H3N2 (A/HongKong/CUHK-22910/2004) (Technical Appendix). A total of 119 hospitalized adults with seasonal influenza A infections were studied (Table 1). Their median age was 71 years (interquartile range [IQR] 57–79 years), and most (66%) had concurrent conditions; ≈5% were profoundly immunosuppressed. Vomiting and diarrhea were reported by 15 (13%) and 7 (6%) patients, respectively. Influenza A viral RNA was detected in 56 of 119 of stool samples, collected at a median interval of 3 days (IQR 3–5 days) from onset (detection rates by study year and virus subtype are shown in Table 2). Detection rate by day from onset ranged from 31% to 63% and showed a trend to decrease toward the end of the week (Figure 1, panel A). Overall, the mean ± SD fecal viral RNA concentration was 4.4 ± 0.8 log10 copies/g of feces and the median (IQR) was 4.2 (3.8–5.0) log10 copies/g of feces; concentrations tended to decrease with longer time elapsed from onset (Figure 1, panel B).
Table 1

Comparisons of baseline clinical and laboratory variables between influenza patients with positive and negative fecal viral RNA detection test results, Hong Kong, 2006–2009*

Patient characteristicsFecal viral RNA–positive, n = 56Fecal viral RNA–negative, n = 63p value
Mean age, y (SD)65.3 (18.6)69.9 (13.4)0.12
Age group, y, no. (%)0.35†
18–497 (13)6 (10)
50–6518 (32)14 (22)
>6531 (55)43 (68)
Female sex, no. (%)33 (59)30 (48)0.27
Interval from illness onset to sample collection <5 d, no. (%)52 (93)53 (84)0.14
Concurrent condition, no. (%)
Any36 (64)43 (68)0.65
Major‡31 (55)37 (59)0.72
Virus isolation, nasopharyngeal aspirates50 (89)49 (77)0.06
Signs and symptoms when care was sought, no. (%)
Fever48 (86)53 (84)1.00
Cough and sputum39 (74)45 (76)0.83
Sore throat15 (28)18 (31)0.84
Rhinorrhea21 (40)21 (36)0.70
Shortness of breath18 (34)27 (46)0.25
Vomiting or diarrhea10 (18)9 (14)0.63
Vomiting7 (13)8 (13)1.00
Diarrhea5 (9)2 (3)0.25
Laboratory parameters when care was sought
Total leukocyte count, × 109 cells/L, median (IQR)7.3 (5.9–8.9)7.9 (6.1–10.3)0.18
Neutrophil count, × 109 cells/L, median (IQR)5.1 (4.2–7.0)6.0 (4.1–7.7)0.22
Lymphocyte count, × 109 cells/L, median (IQR)0.8 (0.6–1.1)0.9 (0.6–1.2)0.20
Lymphocyte count <1.0 × 109 cells/L, no. (%)37 (66)29 (46)0.03
Monocyte count, × 109 cells/L, median (IQR)0.7 (0.5–0.9)0.7 (0.5–0.9)0.51
Platelet count, × 109 cells/L, median (IQR)180 (142–228)196 (156–248)0.20
Alanine aminotransferase level, IU/L, median (IQR)19 (13–32)22 (15–36)0.54
Antiviral treatment, no. (%)
Oseltamivir§35 (63)42 (67)0.70
Zanamivir6 (11)5 (8)0.75
Specimen collected after starting antiviral drugs, no. (%)39 (70)42 (67)0.84
Complication, no. (%)
Any39 (70)44 (70)0.98
Cardiorespiratory¶29 (52)38 (60)0.36
Clinical outcome, no. (%)
ICU admission2 (4)0 (0)0.22
Death00NA
Median duration of hospitalization, d (IQR)6 (4–12)5 (4–13)0.50

*Univariate comparisons of categorical and continuous variables were performed by using Fisher exact test and Mann-Whitney U test or Student t test, whenever appropriate. IQR, interquartile range; ICU, intensive care unit; NA, not applicable.
†Fisher 2×3 exact test.
‡Defined as congestive heart failure; cerebrovascular, neoplastic, chronic liver, and renal diseases; diabetes; ischemic heart disease; or use of immunosuppressant drugs (). Approximately 5% of patients were profoundly immunocompromised.
§Oseltamivir (standard oral regimen, 75 mg 2×/d for 5 d). Amantadine was coadministered to 7 patients during the 2008–09 influenza season.
¶Defined as pneumonia, acute bronchitis, acute exacerbation of chronic respiratory conditions (e.g., chronic obstructive pulmonary disease, asthma); acute coronary syndrome, decompensated heart failure, arrhythmia, or acute cerebrovascular events (8).

Table 2

Fecal detection of seasonal influenza A viral RNA in stool samples, by year of study and virus subtype, Hong Kong, 2006–2009*

Year of studyNo. fecal viral RNA–positive/ no. tested (%)Fecal viral RNA–positive by virus subtype, no. (%)
Fecal viral RNA concentration by virus subtype, log10 RNA copies/g stool, median (IQR)
H1H3H1H3
200611/20 (55)7/7 (100)2/4 (50)5.0 (4.6–6.0)NA
200719/35 (54)0/019/31 (61)NA4.2 (4.0–5.1)
200811/26 (42)1/5 (20)10/21 (48)NA3.9 (3.7–4.4)
200915/38 (39)5/10 (50)10/27 (37)3.9 (3.8–4.1)3.9 (3.7–4.7)
All56/119 (47)13/22 (59)41/83 (49)4.6 (3.9–5.2)4.2 (3.8–5.0)

*Virus subtyping results were unavailable for 9 cases in 2006, 4 cases in 2007, and 1 case in 2009. IQR, interquartile range; NA, not applicable.

Figure 1

Fecal seasonal influenza A viral RNA detection rate and its concentration, by number of days after illness onset, Hong Kong, 2006–2009. A) Fecal viral RNA detection rate. Numbers in bars represent percentage of cases with positive viral RNA detection. B) Fecal viral RNA concentration. Three outliers were omitted from the figure for better illustration. Fecal viral RNA concentration was determined by using quantitative real-time reverse transcription PCR specific for the viral matrix gene and was expressed as log10 RNA copies/g of stool. The lower detection limit of the assay was 3.7 log10 RNA copies/g of stool.

*Univariate comparisons of categorical and continuous variables were performed by using Fisher exact test and Mann-Whitney U test or Student t test, whenever appropriate. IQR, interquartile range; ICU, intensive care unit; NA, not applicable.
†Fisher 2×3 exact test.
‡Defined as congestive heart failure; cerebrovascular, neoplastic, chronic liver, and renal diseases; diabetes; ischemic heart disease; or use of immunosuppressant drugs (). Approximately 5% of patients were profoundly immunocompromised.
§Oseltamivir (standard oral regimen, 75 mg 2×/d for 5 d). Amantadine was coadministered to 7 patients during the 2008–09 influenza season.
¶Defined as pneumonia, acute bronchitis, acute exacerbation of chronic respiratory conditions (e.g., chronic obstructive pulmonary disease, asthma); acute coronary syndrome, decompensated heart failure, arrhythmia, or acute cerebrovascular events (8). *Virus subtyping results were unavailable for 9 cases in 2006, 4 cases in 2007, and 1 case in 2009. IQR, interquartile range; NA, not applicable. Fecal seasonal influenza A viral RNA detection rate and its concentration, by number of days after illness onset, Hong Kong, 2006–2009. A) Fecal viral RNA detection rate. Numbers in bars represent percentage of cases with positive viral RNA detection. B) Fecal viral RNA concentration. Three outliers were omitted from the figure for better illustration. Fecal viral RNA concentration was determined by using quantitative real-time reverse transcription PCR specific for the viral matrix gene and was expressed as log10 RNA copies/g of stool. The lower detection limit of the assay was 3.7 log10 RNA copies/g of stool. In most (77%) viral RNA–positive samples, further H1- or H3-specific PCRs identified 7 cases as H1 and 36 cases as H3; unsuccessful amplification was associated with lower viral (matrix gene) concentrations (median [IQR] 3.9 [3.8–4.1] vs. 4.4 [3.8–5.1] log10 copies/g of stool; p = 0.04). No discrepancy was found between these and the subtyping results of the virus isolates from NPAs. Fecal viral RNA detection rate and concentrations were similar between H1 and H3 subtypes (Table 2). Thirty-eight stool samples from 1 seasonal peak were subjected to virus isolation and viral RNA detection. In 10 cases, cytotoxicity occurred (procedure discontinued); in the remaining 28 cases, 12 were viral RNA positive; only 1 showed virus growth. This sample was from an 82-year-old man with dilated cardiomyopathy hospitalized for seasonal influenza A (H1N1) pneumonia and heart failure; diarrhea was absent. Among 25 confirmed RSV or PIV infections (median [IQR] age 71 [55-79] years), viral RNA was detected in 5 fecal samples (collected at median [IQR] 4 [3-6] days after onset); none was culture positive. Fecal viral RNA positivity was lower compared with that of seasonal influenza viruses (p = 0.01). Patients with positive and negative fecal viral RNA detection results were compared (Table 1). Positive fecal viral RNA detection was associated with younger age, shorter interval from illness onset to sample collection, lymphopenia, and positive virus isolation. Multivariate logistic regression showed that lymphopenia (adjusted odds ratio 2.36, 95% confidence interval 1.02–5.47; p = 0.045) and positive virus isolation in NPAs (adjusted odds ratio 3.76, 95% confidence interval 1.07–13.20; p = 0.039) were significant explanatory variables. No significant association was found between fecal viral RNA detection and clinical outcomes. Fecal viral RNA concentrations were also analyzed, and no association with clinical outcomes was found (data not shown), except for a negative correlation with lymphocyte count (Spearman ρ −0.37, p = 0.047). Lectin histochemical analysis showed that sialic acid α 2,6-Gal (human-like influenza virus receptor) was absent from epithelial surface of small and large intestines and was found only in lamina propria cells. In contrast, sialic acid α 2,3-Gal (avian-like influenza virus receptor) was found on large intestinal epithelial cells and in lamina propria cells. Virus-binding study showed that neither seasonal influenza A (H1N1) nor A (H3N2) virus bind to small and large intestinal epithelial surface, but they bind to a subset of CD45+ leukocytes (Figure 2).
Figure 2

Intestinal distribution of influenza virus receptors and in vitro binding of inactivated seasonal influenza A (H1N1) and A (H3N2) viruses to human duodenal and colonic tissues. Images in the panels labeled Overlay show the green, red, and blue (nuclei counterstain) color channels in the same view. Dotted lines outline basal lining of intestinal epithelium. Arrowheads denote virus-bound cells. Scale bars = 20 µm. A) Double immunofluorescence staining showing that human-like influenza virus receptor sialic acid (SA) α 2,6-Gal; green) was not found on epithelial surface of small and large intestines but in lamina propria cells. Avian-like influenza virus receptor (SAα 2,3-Gal; green) was found on colonic epithelial surface and in lamina propria cells. Part of receptor-positive cells coexpressed CD45 (leukocyte common antigen; red), representing leukocytes. B) In vitro virus binding showing that neither seasonal influenza A (H1N1) nor A (H3N2) viruses bind to epithelial surface of small and large intestines but only to a subset of intestinal CD45+ leukocytes interspersed in the lamina propria and submucosa.

Intestinal distribution of influenza virus receptors and in vitro binding of inactivated seasonal influenza A (H1N1) and A (H3N2) viruses to human duodenal and colonic tissues. Images in the panels labeled Overlay show the green, red, and blue (nuclei counterstain) color channels in the same view. Dotted lines outline basal lining of intestinal epithelium. Arrowheads denote virus-bound cells. Scale bars = 20 µm. A) Double immunofluorescence staining showing that human-like influenza virus receptor sialic acid (SA) α 2,6-Gal; green) was not found on epithelial surface of small and large intestines but in lamina propria cells. Avian-like influenza virus receptor (SAα 2,3-Gal; green) was found on colonic epithelial surface and in lamina propria cells. Part of receptor-positive cells coexpressed CD45 (leukocyte common antigen; red), representing leukocytes. B) In vitro virus binding showing that neither seasonal influenza A (H1N1) nor A (H3N2) viruses bind to epithelial surface of small and large intestines but only to a subset of intestinal CD45+ leukocytes interspersed in the lamina propria and submucosa.

Conclusions

Direct intestinal infection by seasonal influenza viruses seems an unlikely explanation for the frequent fecal detection of viral RNA in the patients reported here. No clinical correlation was shown for RNA positivity (but was shown with lymphopenia and positive virus isolation in NPA, indicating higher virus load), and culture positivity is rare (,,,). Human-like influenza virus receptor is not found to express on normal intestinal epithelial cells (). These findings agree with reports which showed that intestinal cells and tissues do not support efficient replication of seasonal viruses (,), thus their low potential to cause direct intestinal infection. Alternatively, swallowing of virus-containing nasopharyngeal secretions (although it seems inadequate to explain the higher rate of detecting fecal viral RNA than RSV or PIV) and hematogenous dissemination to organs through infected lymphocytes or macrophages in severe influenza cases with high virus load (spillover) are possible explanations for fecal viral RNA detection (,). Our findings on virus receptor distribution and in vitro virus binding to intestinal lamina propria leukocytes lends support to the latter hypothesis. Notably, viral RNA positivity in nonpulmonary tissues infiltrating mononuclear cells without detectable viral particles or antigens or tissue damage has been reported (). Our study does not reject the possibility of seasonal influenza viruses causing occasional, disseminated infection in profoundly immunosuppressed persons because receptor affinity is not absolute (). Conversely, highly pathogenic avian influenza (H5N1) and pandemic (H1N1) 2009 viruses have the ability to bind to avian-like influenza virus receptors on colonic epithelium and to replicate efficiently in intestinal cells and tissues (). Their enhanced potential to cause direct intestinal infections and fecal–oral transmission deserve further investigation.

Technical Appendix

Technical details used in the fecal detection and isolation of viruses.
  15 in total

1.  Significance of seasonal influenza viruses in the stool of pediatric patients.

Authors:  Daisuke Tamura; Motoko Fujino; Makoto Ozawa; Kiyoko Iwatsuki-Horimoto; Hideo Goto; Yuko Sakai-Tagawa; Taisuke Horimoto; Mari Nirasawa; Yoshihiro Kawaoka
Journal:  Pediatr Infect Dis J       Date:  2010-06       Impact factor: 2.129

2.  The 2009 pandemic H1N1 and triple-reassortant swine H1N1 influenza viruses replicate efficiently but elicit an attenuated inflammatory response in polarized human bronchial epithelial cells.

Authors:  Hui Zeng; Claudia Pappas; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

3.  Outcomes of adults hospitalised with severe influenza.

Authors:  N Lee; K W Choi; P K S Chan; D S C Hui; G C Y Lui; B C K Wong; R Y K Wong; W Y Sin; W M Hui; K L K Ngai; C S Cockram; R W M Lai; J J Y Sung
Journal:  Thorax       Date:  2010-06       Impact factor: 9.139

4.  Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia.

Authors:  Nelson Lee; Paul K S Chan; Chun Kwok Wong; Ka-Tak Wong; Kin-Wing Choi; Gavin M Joynt; Philip Lam; Martin C W Chan; Bonnie C K Wong; Grace C Y Lui; Winnie W Y Sin; Rity Y K Wong; Wai-Yip Lam; Apple C M Yeung; Ting-Fan Leung; Hing-Yu So; Alex W Y Yu; Joseph J Y Sung; David S C Hui
Journal:  Antivir Ther       Date:  2011

5.  Clinical characteristics of children with influenza A virus infection requiring hospitalization.

Authors:  Ying-Hsiang Wang; Yhu-Chering Huang; Luan-Yin Chang; Hsiu-Tsun Kao; Pen-Yi Lin; Chung-Guei Huang; Tzou-Yien Lin
Journal:  J Microbiol Immunol Infect       Date:  2003-06       Impact factor: 4.399

Review 6.  Innate immune responses to influenza A H5N1: friend or foe?

Authors:  Joseph Sriyal Malik Peiris; Chung Yan Cheung; Connie Yin Hung Leung; John Malcolm Nicholls
Journal:  Trends Immunol       Date:  2009-10-26       Impact factor: 16.687

7.  Differences in clinical features between influenza A H1N1, A H3N2, and B in adult patients.

Authors:  Masahide Kaji; Aya Watanabe; Hisamichi Aizawa
Journal:  Respirology       Date:  2003-06       Impact factor: 6.424

8.  Long-term shedding of influenza A virus in stool of immunocompromised child.

Authors:  Benjamin A Pinsky; Samantha Mix; Judy Rowe; Sheryl Ikemoto; Ellen J Baron
Journal:  Emerg Infect Dis       Date:  2010-07       Impact factor: 6.883

9.  Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.

Authors:  Menno D de Jong; Cameron P Simmons; Tran Tan Thanh; Vo Minh Hien; Gavin J D Smith; Tran Nguyen Bich Chau; Dang Minh Hoang; Nguyen Van Vinh Chau; Truong Huu Khanh; Vo Cong Dong; Phan Tu Qui; Bach Van Cam; Do Quang Ha; Yi Guan; J S Malik Peiris; Nguyen Tran Chinh; Tran Tinh Hien; Jeremy Farrar
Journal:  Nat Med       Date:  2006-09-10       Impact factor: 53.440

10.  Influenza virus infection among pediatric patients reporting diarrhea and influenza-like illness.

Authors:  Charisma Dilantika; Endang R Sedyaningsih; Matthew R Kasper; Magdarina Agtini; Erlin Listiyaningsih; Timothy M Uyeki; Timothy H Burgess; Patrick J Blair; Shannon D Putnam
Journal:  BMC Infect Dis       Date:  2010-01-07       Impact factor: 3.090

View more
  16 in total

1.  Viral variant-resolved wastewater surveillance of SARS-CoV-2 at national scale.

Authors:  Fabian Amman; Rudolf Markt; Lukas Endler; Sebastian Hupfauf; Benedikt Agerer; Anna Schedl; Lukas Richter; Melanie Zechmeister; Martin Bicher; Georg Heiler; Petr Triska; Matthew Thornton; Thomas Penz; Martin Senekowitsch; Jan Laine; Zsofia Keszei; Peter Klimek; Fabiana Nägele; Markus Mayr; Beatrice Daleiden; Martin Steinlechner; Harald Niederstätter; Petra Heidinger; Wolfgang Rauch; Christoph Scheffknecht; Gunther Vogl; Günther Weichlinger; Andreas Otto Wagner; Katarzyna Slipko; Amandine Masseron; Elena Radu; Franz Allerberger; Niki Popper; Christoph Bock; Daniela Schmid; Herbert Oberacher; Norbert Kreuzinger; Heribert Insam; Andreas Bergthaler
Journal:  Nat Biotechnol       Date:  2022-07-18       Impact factor: 68.164

Review 2.  Use of ex vivo and in vitro cultures of the human respiratory tract to study the tropism and host responses of highly pathogenic avian influenza A (H5N1) and other influenza viruses.

Authors:  Renee W Y Chan; Michael C W Chan; John M Nicholls; J S Malik Peiris
Journal:  Virus Res       Date:  2013-05-15       Impact factor: 3.303

3.  Fecal influenza in mammals: selection of novel variants.

Authors:  Zeynep A Koçer; John Obenauer; Hassan Zaraket; Jinghui Zhang; Jerold E Rehg; Charles J Russell; Robert G Webster
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

4.  Influenza virus detection in the stool of children with acute gastroenteritis.

Authors:  Jianling Xie; Xiao-Li Pang; Gillian A M Tarr; Yuan Mu; Ran Zhuo; Linda Chui; Bonita E Lee; Otto G Vanderkooi; Phillip I Tarr; Samina Ali; Shannon E MacDonald; Stephen B Freedman
Journal:  J Clin Virol       Date:  2020-08-01       Impact factor: 3.168

Review 5.  Diminished immune responses with aging predispose older adults to common and uncommon influenza complications.

Authors:  Spencer R Keilich; Jenna M Bartley; Laura Haynes
Journal:  Cell Immunol       Date:  2019-10-10       Impact factor: 4.868

6.  Simultaneous investigation of influenza and enteric viruses in the stools of adult patients consulting in general practice for acute diarrhea.

Authors:  Christophe Arena; Jean Pierre Amoros; Véronique Vaillant; Katia Balay; Roxane Chikhi-Brachet; Laurent Varesi; Jean Arrighi; Thierry Blanchon; Fabrice Carrat; Thomas Hanslik; Alessandra Falchi
Journal:  Virol J       Date:  2012-06-18       Impact factor: 4.099

7.  Profiling of Intestinal Microbiota in Patients Infected with Respiratory Influenza A and B Viruses.

Authors:  Hebah A Al Khatib; Shilu Mathew; Maria K Smatti; Nahla O Eltai; Sameer A Pathan; Asmaa A Al Thani; Peter V Coyle; Muna A Al Maslamani; Hadi M Yassine
Journal:  Pathogens       Date:  2021-06-17

Review 8.  Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know?

Authors:  Laetitia Minodier; Remi N Charrel; Pierre-Emmanuel Ceccaldi; Sylvie van der Werf; Thierry Blanchon; Thomas Hanslik; Alessandra Falchi
Journal:  Virol J       Date:  2015-12-12       Impact factor: 4.099

9.  Spillover of pH1N1 to swine in Cameroon: an investigation of risk factors.

Authors:  Brenda Larison; Kevin Y Njabo; Anthony Chasar; Trevon Fuller; Ryan J Harrigan; Thomas B Smith
Journal:  BMC Vet Res       Date:  2014-03-04       Impact factor: 2.741

10.  Evaluation of a smartphone-based rapid fluorescent diagnostic system for H9N2 virus in specific-pathogen-free chickens.

Authors:  Seon-Ju Yeo; Bui Thi Cuc; Haan Woo Sung; Hyun Park
Journal:  Arch Virol       Date:  2016-06-10       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.